You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for (S)-3,5-DHPG
(S)-3,5-DHPG is a selective group I mGlu receptor agonist.
Racemate also available.
Technical Data for (S)-3,5-DHPG
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for (S)-3,5-DHPG
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for (S)-3,5-DHPG
The following data is based on the product molecular weight 183.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||10.92 mL||54.6 mL||109.19 mL|
|2.5 mM||2.18 mL||10.92 mL||21.84 mL|
|5 mM||1.09 mL||5.46 mL||10.92 mL|
|25 mM||0.22 mL||1.09 mL||2.18 mL|
References for (S)-3,5-DHPG
References are publications that support the biological activity of the product.
Schoepp et al (1994) 3,5-Dihydroxyphenylglycine is a highly selective agonist for phosphoinositide-linked metabotropic glutamate receptors in the rat hippocampus. J.Neurochem. 63 769 PMID: 8035201
Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493 PMID: 8730745
Wisniewski and Car (2002) (S)-3,5-DHPG: a review. CNS Drug Rev. 8 101 PMID: 12070529
Baker et al (1995) Enzymatic resolution and pharmacological activity of the enantiomers of 3,5-dihydroxyphenylglycine, a metabotropic glutamate receptor agonist. Bioorg.Med.Chem.Lett. 5 223
If you know of a relevant reference for (S)-3,5-DHPG, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (S)-3,5-DHPG, (S)-3,5-DHPG supplier, Selective, group, I, agonists, Active, enantiomer, Group, Receptors, mGlu1, mGlu5, mGluR1, mGluR5, Glutamate, Metabotropic, (Metabotropic), 0805, Tocris Bioscience
37 Citations for (S)-3,5-DHPG
Citations are publications that use Tocris products. Selected citations for (S)-3,5-DHPG include:
Ifrim et al (2015) Single-Molecule Imaging of PSD-95 mRNA Translation in Dendrites and Its Dysregulation in a Mouse Model of Fragile X Syndrome. PLoS One 35 7116 PMID: 25948262
Henderson et al (2015) A Low Affinity GCaMP3 Variant (GCaMPer) for Imaging the Endoplasmic Reticulum Calcium Store. J Neurosci 10 e0139273 PMID: 26451944
Aguilar-Valles et al (2015) Inhibition of Group I Metabotropic Glutamate Receptors Reverses Autistic-Like Phenotypes Caused by Deficiency of the Translation Repressor eIF4E Binding Protein 2. Neuropharmacology 35 11125 PMID: 26245973
Fairless et al (2013) Membrane potential measurements of isolated neurons using a voltage-sensitive dye. PLoS One 8 e58260 PMID: 23516458
Jung et al (2005) Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Proc Natl Acad Sci U S A 68 1196 PMID: 16051747
Jacob et al (2005) Signaling microdomains regulate inositol 1,4,5-trisphosphate-mediated intracellular calcium transients in cultured neurons. Proc Natl Acad Sci U S A 25 2853 PMID: 15772345
Cai et al (2004) Activity-dependent expression of inositol 1,4,5-trisphosphate receptor type 1 in hippocampal neurons. PLoS One 279 23691 PMID: 15016804
Paul et al (2019) Differential Regulation of Syngap1 Translation by FMRP Modulates eEF2 Mediated Response on NMDAR Activity. Front Mol Neurosci 12 97 PMID: 31143100
Peterfi et al (2012) Endocannabinoid-mediated long-term depression of afferent excitatory synapses in hippocampal pyramidal cells and GABAergic interneurons. J Neurosci 32 14448 PMID: 23055515
Gregg et al (2012) Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J Neurosci 32 9457 PMID: 22787031
Wu et al (2004) Group I metabotropic glutamate receptor activation produces a direct excitation of identified septohippocampal cholinergic neurons. J Neurophysiol 92 1216 PMID: 15044519
Paladini et al (2003) DA controls the firing pattern of DA neurons via a network feedback mechanism. Sci Rep 100 2866 PMID: 12604788
Musella (2017) A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum. Sci Rep 7 7363 PMID: 28779174
Zhao et al (2011) Dual regulation of fragile X mental retardation protein by group I metabotropic glutamate receptors controls translation-dependent epileptogenesis in the hippocampus. J Neurosci 31 725 PMID: 21228181
Hashimotodani et al (2017) LTP at Hilar Mossy Cell-Dentate Granule Cell Synapses Modulates Dentate Gyrus Output by Increasing Excitation/Inhibition Balance. Neuron 95 928 PMID: 28817805
Tang and Alger (2015) Homer protein-metabotropic glutamate receptor binding regulates endocannabinoid signaling and affects hyperexcitability in a mouse model of fragile X syndrome. J Neurosci 35 3938 PMID: 25740522
Tang et al (2015) Stimulation-evoked Ca2+ signals in astrocytic processes at hippocampal CA3-CA1 synapses of adult mice are modulated by glutamate and ATP. J Neurosci 35 3016 PMID: 25698739
Pollard et al (2014) Modulation of neuronal microcircuit activities within the medial prefrontal cortex by mGluR5 positive allosteric modulator. J Psychopharmacol 28 935 PMID: 25031220
Careaga et al (2014) Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome. J Neuroinflammation 11 110 PMID: 24942544
McQuail et al (2013) Hippocampal Gαq/11 but not Gαo-coupled receptors are altered in aging. PLoS One 70 63 PMID: 23347951
Kuribayashi et al (2013) The role of metabotropic glutamate receptor 5 on the stromal cell-derived factor-1/CXCR4 system in oral cancer. J Biol Chem 8 e80773 PMID: 24236200
Taman and Ribeiro (2011) Characterization of a truncated metabotropic glutamate receptor in a primitive metazoan, the parasitic flatworm Schistosoma mansoni. PLoS One 6 e27119 PMID: 22069494
Bozdagi et al (2012) Haploinsufficiency of Cyfip1 produces fragile X-like phenotypes in mice. J Neurosci 7 e42422 PMID: 22900020
Westmark and Malter (2007) FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol 5 e52 PMID: 17298186
Xu et al (2007) Calpain-mediated mGluR1alpha truncation: a key step in excitotoxicity. Neuron 53 399 PMID: 17270736
Fukunaga et al (2007) Potent and specific action of the mGlu1 antagonists YM-298198 and JNJ16259685 on synaptic transmission in rat cerebellar slices. Br J Pharmacol 151 870 PMID: 17502847
Nakamoto et al (2007) Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci U S A 104 15537 PMID: 17881561
Hellmer et al (2018) A group I metabotropic glutamate receptor controls synaptic gain between rods and rod bipolar cells in the mouse retina. Physiol Rep 6 e13885 PMID: 30338673
Morel et al (2018) JIP1-Mediated JNK Activation Negatively Regulates Synaptic Plasticity and Spatial Memory. J Neurosci 38 3708 PMID: 29540552
Pallo et al (2016) Mechanisms of tau and Aβ-induced excitotoxicity. Brain Res 1634 119 PMID: 26731336
Filippov et al (2010) The scaffold protein NHERF2 determines the coupling of P2Y1 nucleotide and mGluR5 glutamate receptor to different ion channels in neurons. Mol Pharmacol 30 11068 PMID: 20720114
Fu and Pol (2010) Kisspeptin directly excites anorexigenic proopiomelanocortin neurons but inhibits orexigenic neuropeptide Y cells by an indirect synaptic mechanism. J Neurosci 30 10205 PMID: 20668204
Pan et al (2010) Ictal activity induced by group I metabotropic glutamate receptor activation and loss of afterhyperpolarizations. Neuropharmacology 59 86 PMID: 20385148
Kuang et al (2006) Ancestral reconstruction of the ligand-binding pocket of Family C G protein-coupled receptors. J Neurosci 103 14050 PMID: 16966606
Zhao (2014) BDNF-endocannabinoid interactions at neocortical inhibitory synapses require phospholipase C signaling. J Neurophysiol 111 1008 PMID: 24335212
Ruangkittisakul et al (2006) High sensitivity to neuromodulator-activated signaling pathways at physiological [K+] of confocally imaged respiratory center neurons in on-line-calibrated newborn rat brainstem slices. J Neurosci 26 11870 PMID: 17108160
El-Kouhen et al (2006) Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist. Br J Pharmacol 149 761 PMID: 17016515
Do you know of a great paper that uses (S)-3,5-DHPG from Tocris? Please let us know.
Reviews for (S)-3,5-DHPG
Average Rating: 5 (Based on 2 Reviews.)
Have you used (S)-3,5-DHPG?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Retinal dissections were performed in HEPES-buffered extracellular solution containing glutamate inhibitor cocktail 100 umol/L
Used this compound to induce Group I mGluR-dependent LTD in acute brain slices from the mouse hippocampus at a concentration of 50μM. Reliably induces LTD to 50-80% of baseline.
Pay close attention to enantiomer. Some report that R,S-DHPG is not as effective at inducing LTD as S-DHPG alone, which is something I will anecdotally corroborate.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.